An evidence-based tool to guide the identification and outpatient treatment of patients with low-risk pulmonary embolism.
This bedside tool is available in our emPOC app. Available exclusively to ACEP Members.
- Untreated substance use disorder
- Dysregulated psychiatric disease
- Lack of ability to follow up (e.g. transportation)
- Lack of ability to obtain medications (e.g. no insurance)
- Any other condition that the physician deems as high risk for noncompliance
- RV:LV ratio >1
- Main pulmonary artery PE or saddle PE
- Clot visualized in the heart
- Echocardiogram should be considered if CTPA shows evidence of right ventricular strain (e.g. RV:LV ratio >1)
- Right ventricular hypokinesis
- Bowing of the intraventricular septum (i.e. D-sign)
- Clot visualized in the heart
- Troponin elevated
- Lower extremity venous imaging should be considered when a patient has leg pain, swelling, redness, or evidence of venous distension
- DVT in iliofemoral vein
- Evidence of phlegmasia cerulea or alba dolens
- New right heart strain pattern, including;
- Right bundle branch block
- Deep T wave inversions in anterior precordial leads
- S1Q3T3 pattern
- New onset atrial fibrillation
- Active bleeding
- Previous clinically significant bleeding including: Bleeding in a critical area or organ (e.g. intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, intramuscular with compartment syndrome, hemoptysis, airway bleeding), or other bleeding requiring intervention.
- Recent major surgery
- Recent major trauma (including closed head injury without bleeding)
- Recent stroke
- Malignancy in a critical site (e.g. intracranial, spinal, ocular, oropharyngeal, retroperitoneal)
- Thrombocytopenia (platelet count <75,000)
- Cirrhosis or severe alcohol use disorder
- High risk of falling
- Use of medications that interact with anticoagulants or significantly increase risk of bleeding
- LMWH: enoxaparin sodium (Lovenox), 1 mg/kg SC twice daily or dalteparin sodium (fragmin), 200 IU/kg SC daily
- Fondaparinux: 5 mg (body weight <50 kg), 7.5 mg (50 to 100 kg), or 10 mg (>100 kg) SC once daily
- A "Med to Bed" or similar programs whereby patients are discharged with their medications in-hand
- The patient's pharmacy may be able to confirm that the anticoagulant is covered by their insurance, without the need for a prior authorization
- A "starter pack" of a DOAC can assist patients in successfully transitioning their dose at week 1 or 3
Developed by the ACEP Expert Panel on Low-Risk Pulmonary Embolism
and Low-Risk Deep Vein Thrombosis
Reviewed by the ACEP Clinical Resource Review Committee
Christopher Kabrhel MD, MPH, FACEP, FAAEM (chair) Anna Marie Chang, MD Jackeline Hernandez-Nino, MD Alice M. Mitchell, MD, FACEP Rachel Rosovsky, MD, MPH David R. Vinson, MD, FACEP Stephen J. Wolf, MD, FACEP
Jerry Anderson Riane V. Gay, MPA, CAE Liz Muth
Questions, Contact us today!
The American College of Emergency Physicians (ACEP) makes every effort to ensure that contributors and editors of its resources are knowledgeable subject matter experts and that they used their best efforts to ensure accuracy of the content. However, it is the responsibility of each user to personally evaluate the content and judge its suitability for use in his or her medical practice in the care of a particular patient. Users are advised that the statements and opinions expressed in this resource are provided as recommendations of the contributors and editors at the time of publication and should not be construed as official College policy. ACEP acknowledges that, as new medical knowledge emerges, best practice recommendations can change faster than published content can be updated. ACEP recognizes the complexity of emergency medicine and makes no representation that this resource serves as an authoritative resource for the prevention, diagnosis, treatment, or intervention for any medical condition, nor should it be used as the basis for the definition of or the standard of care that should be practiced by all health care providers at any particular time or place. To the fullest extent permitted by law, and without limitation, ACEP expressly disclaims all liability for errors or omissions contained within this resource, and for damages of any kind or nature, arising out of use, reference to, reliance on, or performance of such information.
Copyright 2021, American College of Emergency Physicians, Dallas, Texas. All rights reserved. Produced in the United States of America. Except as permitted under the United States Copyright Act of 1976, no part of this resource may be reproduced or distributed in any form or by any means or stored in a database or retrieval system without prior written permission of the publisher.
Requests for permission should be sent here.